Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease

Journal of Oncology Pharmacy Practice

Volumn 22, Issue 2, 2016, Pages 289-302

  Ashjian, Emily ^a   Redic, Kimberly ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

investigational drugs; Multiple myeloma; pharmacy; refractory; relapsed; supportive care

Indexed keywords

CARFILZOMIB; DARATUMUMAB; ELOTUZUMAB; FILANESIB; GANETESPIB; IBRUTINIB; ISATUXIMAB; IXAZOMIB; OPROZOMIB; PANOBINOSTAT; POMALIDOMIDE; QUISINOSTAT; RICOLINOSTAT; SALINOSPORAMIDE A; SELINEXOR; VENETOCLAX; VORINOSTAT; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; IMMUNOLOGIC FACTOR; PROTEASOME INHIBITOR; THALIDOMIDE;

CANCER RECURRENCE; FOOD AND DRUG ADMINISTRATION; HUMAN; MULTIPLE MYELOMA; PHARMACIST; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANALOGS AND DERIVATIVES; CLINICAL TRIAL (TOPIC); PROCEDURES; PROFESSIONAL STANDARD; TREATMENT OUTCOME; TRENDS; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; PHARMACISTS; PROFESSIONAL ROLE; PROTEASOME INHIBITORS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84959358879     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155215572036     Document Type: Review

References (101)

1. American Cancer Society. Cancer facts & figures 2014, Atlanta: American Cancer Society, 2014.
2. Surveillance, Epidemiology, and End Results (SEER) Cancer Statistics Factsheets: Myeloma. National Cancer Institute 2013. Bethesda, MD, http://seer.cancer.gov/statfacts/html/mulmy.html (accessed 20 December 2013).
3. Kyle RA, Rajkumar SA,. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3-9.
4. Kyle RA, Child AJ, Anderson K, et al. Criteria for the classification of monoclonal gammopathies, multiple myeloma, and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757.
5. National Comprehensive Cancer Network. Multiple Myeloma. Version 2.2014.
6. Mikhael JR, Dingli D, Roy V, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc 2013; 88: 360-376.
7. Kumar SK, Therneau TM, Gertz MA, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 2004; 79: 867-874.
8. Highsmith KN, Chen SE, Horowitz S,. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma. Pharmacotherapy 2014; 34: 927-940.
9. Pomalyst [package insert]. Summit, NJ: Celgene, 2013.
10. Lacy MQ,. ''IM iD''eally treating multiple myeloma. Blood 2013; 121: 1926-1927.
11. Revlimid [package insert]. Summit, NJ: Celgene, 2013.
12. Matous J, Siegel D, Duong HK, et al. MM-008 trial: Pharmacokinetics (PK) and tolerability of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in relapsed/refractory multiple myeloma (RRMM) patients with renal impairment. J Clin Oncol 2013; suppl: abstr 8585.
13. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009; 27: 5008-5014.
14. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 2010; 24: 1934-1939.
15. San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14: 1055-1066.
16. Oncotherapeutics. A phase 1/2 study of pomalidomide, dexamethasone, and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), http://clinicaltrials.gov/ct2/show/NCT01541332?term=NCT01541332 NLM Identifier: NCT01541332 (2000, accessed 26 Feb 2014).
17. Berenson JR, Hilger JD, Klein L, et al. Pomalidomide, dexamethasone, and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma: results from a phase 1/2 trial. 2013; ASH Annual Meeting Abstr 3218.
18. Celgene Corporation. Safety and efficacy of pomalidomide, bortezomib, and low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma (OPTIMISMM). In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), http://clinicaltrials.gov/ct2/show/NCT01734928 NLM Identifier: NCT01734928 (2000, accessed 26 Feb 2014).
19. H. Lee Moffitt Cancer Center and Research Institute. Pomalidomide in combination with high dose dexamethasone and oral cyclophosphamide. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), http://clinicaltrials.gov/ct2/show/NCT01432600?term=NCT01432600 NLM Identifier: NCT01432600 (2000, accessed 26 Feb 2014).
20. University of Chicago. Carfilzomib, pomalidomide, and dexamethasone in treating patients with relapsed or refractory multiple myeloma. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), http://clinicaltrials.gov/ct2/show/NCT01665794?term=NCT01665794 NLM Identifier: NCT01665794 (2000, accessed 26 Feb 2014).
21. Arastu-Kapur S, Anderl JL, Kraus M, et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res 2011; 17: 2734-2743.
22. Kyprolis [package insert]. South San Francisco, CA: Onyx Pharmaceuticals Inc.; 2013.
23. Berenson JR, Klein L, Rifkin RM, et al. A Phase 1, dose-escalation study (CHAMPION-1) investigating weekly carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma. 2013; ASH Annual Meeting Abstr 1934.
24. Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012; 120: 2817-2825.
25. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015; 372: 142-152.
26. Onyx Therapeutics, Inc. A study of carfilzomib plus best supportive care in subjects with relapsed and refractory multiple myeloma (FOCUS). In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), http://clinicaltrials.gov/ct2/show/NCT01279694?term=NCT01279694 NLM Identifier: NCT01302392 (2000, accessed 26 Feb 2014).
27. Onyx Pharmaceuticals. Phase 3 study with carfilzomib and dexamethasone versus velcade and dexamethasone for relapsed multiple myeloma patients (ENDEAVOR). In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), http://clinicaltrials.gov/ct2/show/NCT01568866?term=NCT01568866 NLM Identifier: NCT01568866 (2000, accessed 26 Feb 2014).
28. Bringhen S, Cerrato C, Petrucci MT, et al. A phase II study with carfilzomib, cyclophosphamide and dexamethasone (CCd) for newly diagnosed multiple myeloma 2013; ASH Annual Meeting Abstr 685.
29. Korde N, Zingone A, Kwok ML, et al. Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide extended dosing (CRD-R) induces high rates of MRD negativity in newly diagnosed multiple myeloma (MM) patients 2013; ASH Annual Meeting Abstr 653.
30. Lin P, Owens R, Tricot G, et al. Flow cytometric immunmophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 2004; 121: 482-488.
31. Deaglio S, Mehta K, Malavasi F,. Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk Res 2001; 25: 1-12.
32. Gallay N, Anani L, Lopez A, et al. The role of platelet/endothelial cell adhesion molecule-1 (CD31) and CD38 antigens in marrow microenvironmental retention of acute myelogenous leukemia cells. Cancer Res 2007; 67: 8624-8632.
33. Partida-Sanchez S, Cockayne DA, Monard S, et al. Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo. Nature Med 2001; 7: 1209-1216.
34. de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011; 186: 1840-1848.
35. van der Veer MS, de Weers M, van Kessel B, et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 2011; 96: 284-290.
36. Genmab. Daratumumab (HuMax-CD38) safety study in multiple myeloma. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), http://clinicaltrials.gov/ct2/show/NCT00574288?term=NCT00574288 NLM Identifier: NCT00574288 (2000, accessed 26 Feb 2014).
37. Plesner T, Arkenau T, Lokhorst H, et al. Preliminary safety and efficacy data of daratumumab in combination with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma. ASH 2013 Annual Meeting Abstract 1986.
38. Genmab. Daratumumab in combination with lenalidomide and dexamethasone in relapsed and relapsed-refractory multiple myeloma. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), http://clinicaltrials.gov/ct2/show/NCT01615029?term=NCT01615029 NLM Identifier: NCT01615029 (2000, accessed 26 Feb 2014).
39. Janssen Research and Development, LLC. An efficacy and safety study of daratumumab in patients with multiple myeloma who have received at least 3 prior lines of therapy (including a proteasome inhibitor (PI) and immunomodulatory drug [ImiD]) or are double refractory to a PI and an ImiD. In: ClinicalTrials.gov[Internet]. National Library of Medicine (US), http://clinicaltrials.gov/ct2/show/NCT01985126?term=%28NCT01985126%29&rank=1. NLM Identifier: NCT01985126 (2000, accessed 16 March 2014).
40. Janssen Research and Development, LLC. A study comparing daratumumab, lenalidomide, and dexamethasone with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma. In: ClinicalTrials.gov[Internet]. National Library of Medicine (US), http://clinicaltrials.gov/ct2/show/NCT02076009?term=daratumumab&rank=5. NLM Identifier: NCT02076009 (2000, accessed 16 March 2014).
41. Janssen Research and Development, LLC. A study of JNJ-54767414 (HuMax CD38) (Anti-CD38 monoclonal antibody) in combination with backbone treatments for the treatment of patients with multiple myeloma. In: ClinicalTrials.gov[Internet]. National Library of Medicine (US), http://clinicaltrials.gov/ct2/show/NCT01998971?term=daratumumab&rank=3. NLM Identifier: NCT01998971 (2000, accessed 16 March 2014).
42. Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res 2008; 14: 2775-2784.
43. Tai YT, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 2008; 112: 1329-1337.
44. Zonder JA, Mohrbacher AF, Singhal, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 2012; 120: 552-559.
45. Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasoen in relapsed or refractory multiple myeloma. J Clin Oncol 2012; 30: 1953-1959.
46. Lonial S, Jagannath S, Moreau P, et al. Phase I/II study of elotuzumab plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma: updated phase II results and Phase I/II long-term safety. J Clin Oncol 2013; suppl abstr 8542.
47. Jakubowiak AJ, Benson DM, Bensinger W, et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol 2012; 30: 1960-1965.
48. Bristol-Myers Squibb. Phase III study of lenalidomide and dexamethasone with or without elotuzumab to treat newly diagnosed, previously untreated multiple myeloma (ELOQUENT-1). In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), http://clinicaltrials.gov/ct2/show/NCT01335399?term=NCT01335399 NLM Identifier: NCT01335399 (2000, accessed 26 Feb 2014).
49. Bristol-Myers Squibb. Phase III study of lenalidomide and dexamethasone with or without elotuzumab to treat relapsed or refractory multiple myeloma (ELOQUENT-2). In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), http://clinicaltrials.gov/ct2/show/NCT01239797?term=NCT01239797 NLM Identifier: NCT01239797 (2000, accessed 26 Feb 2014).
50. Deckert J, Wetzel MC, Bartle LM, et al. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res 2014; 20: 4574-4583.
51. Martin TG, Strickland SA, Glen M, et al. SAR650984, a CD38 monoclonal antibody in patients with selected CD38+ hematological malignancies-data from a dose-escalation phase I study. ASH Annual Meeting 2013; Abstr 264.
52. Sanofi. Phase I SAR650984 combination with lenalidomide (LenCombo). ClinicalTrials.gov [Internet]. National Library of Medicine (US), https://clinicaltrials.gov/ct2/show/NCT01749969?term=sar650984&rank=1. NLM Identifier: NCT01749969 (2000, accessed 15 Dec 2014).
53. Hideshima T, Richardson PG, Anderson KC,. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther 2011; 10: 2034-2042.
54. Weber DM, Graef T, Hussein M, et al. Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 2012; 12: 319-324.
55. Siegel SS, Dimopoulos MA, Yoon SS, et al. Vantage 095: Vorinostat in combination with bortezomib in salvage multiple myeloma patients: final study results of a global phase 2b trial. Blood (ASH annual meeting abstracts) 2011; 118: abstract 480.
56. Dimopoulos M, Siegel DS, Lonial S, et al. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol 2013; 14: 1129-1140.
57. Richardson PG, Schlossman RL, Alsina M, et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 2013; 122: 2331-2337.
58. Novartis Pharmaceuticals. Panobinostat or placebo with bortezomib and dexamethasone in patients with relapsed multiple myeloma (PANORAMA-1). In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), http://clinicaltrials.gov/ct2/show/NCT01023308?term=panobinostat+panorama+1&rank=1. NLM Identifier: NCT01023308 (2000, accessed 16 March 2014).
59. Novartis Pharmaceuticals. Novartis investigational compound LBH589 significantly extended time without disease progression in Phase III multiple myeloma study, http://www.novartis.com/newsroom/media-releases/en/2013/1748147.shtml (accessed 6 Dec 2013).
60. Santo L, Hideshima T, Kung AL, et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 2012; 119: 2579-2589.
61. Acetylon Pharmaceuticals Incorporated. Study of ACY-1215 alone and in combination with bortezomib and dexamethasone in multiple myeloma. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), https://clinicaltrials.gov/ct2/show/NCT01323751?term=acy-1215&rank=1. NLM Identifier: NCT01323751 (2000, accessed 1 Nov 2014).
62. Raje N, Vogl DT, Hari PN, et al. ACY-1215, a selective histone deaceytlase (HDAC) 6 inhibitor: interim results of combination therapy with bortezomib in patients with multiple myeloma. Blood 2013; 122: Abstract 759-Abstract 759.
63. Acetylon Pharmaceuticals Incorporated. Study of ACY-1215 in combination with lenalidomide and dexamethasone in multiple myeloma. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), https://clinicaltrials.gov/ct2/show/NCT01583283?term=acy-1215&rank=3. NLM Identifier: NCT01583283 (2000, accessed 1 Nov 2014).
64. Yee A, Vorhees P, Bensinger WI, et al. ACY-1215, a selective histone deacetylase (HDAC) 6 inhibitor, in combination with lenalidomide and dexamethasone is well tolerated without dose limiting toxicity in patients with multiple myeloma at doses demonstrating biologic activity: Interim results of a phase Ib trial. Blood 2013; 122: Abstract 3190-Abstract 3190.
65. Acetylon Pharmaceuticals Incorporated. ACY-1215 (Ricolinostat) in combination with pomalidomide and low-dose dexamethasone in relapsed-and-refractory multiple myeloma. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), https://clinicaltrials.gov/ct2/show/NCT01997840?term=acy-1215&rank=4. NLM Identifier: NCT01997840 (2000, accessed 1 Nov 2014).
66. Acetylon Pharmaceuticals Incorporated. Phase Ib study evaluating ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone in relapsed-and-refractory multiple myeloma. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), https://clinicaltrials.gov/ct2/show/NCT02189343?term=acy-1215&rank=6NLM Identifier: NCT02189343 (2000, accessed 1 Nov 2014).
67. Moreau P, Facon T, Touzeau C, et al. Phase Ib dose escalation study of oral quisinostat, a histone deacetylase inhibitor (HDACi) in combination with Velcade (bortezomib) and dexamethasone for patients with relapsed multiple myeloma (MM). ASH 2013 annual meeting abstract 1932.
68. Janssen Research and Development, LLC. A dose escalation study of the histone deacetylase inhibitor (HDACi) JNJ 26481585 in combination with Velcade (bortezomib) and dexamethasone for patients with relapsed multiple myeloma. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), http://clinicaltrials.gov/ct2/show/NCT01464112?term=01464112&rank=1. NLM Identifier: NCT01464112 (2000, accessed 16 March 2014).
69. Kupperman E, Lee EC, Cao Y, et al. Evaluation of proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 2010; 70: 1970-1980.
70. Kumar S, Bensinger W, Zimmerman TM, et al. Weekly MLN9708, an investigational oral proteasome inhibitor (PI), in relapsed/refractory multiple myeloma (MM): Results from a phase I study after full enrollment. J Clin Oncol 2013 (suppl): abstr 8514-abstr 8514.
71. Kumar S, Berdeja JG, Niesvizky R, et al. A phase 1/2 study of weekly MLN9708, an investigational oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (MM). ASH Annual Meeting 2012; Abstr 332.
72. Richardson PG, Hofmeister CC, Rosenbaum CA, et al. Twice-weekly oral MLN9708 (Ixazomib citrate), an investigational proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma: Final phase 1 or phase 2 data. ASH Annual Meeting 2013; Abstr 535.
73. Millennium Pharmaceuticals, Inc. A phase 3 study comparing oral MLN9708 plus lenalidomide and dexamethasone versus placebo plus lenalidomide and dexamethasone in adult patients with relapsed and/or refractory multiple myeloma. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), http://clinicaltrials.gov/ct2/show/NCT01564537?term=TOURMALINE-MM&rank=1. NLM Identifier: NCT01564537 (2000, accessed 18 May 2014).
74. Richardson PG, Spencer A, Cannell P, et al. Phase I clinical evaluation of twice-weekly marizomib (NPI-0052), a novel proteasome inhibitor, in patients with relapsed/refractory multiple myeloma. ASH Annual Meeting Abstract. Blood 2011; 118: 140-1[Abstr 302].
75. Triphase Research and Development I Corporation. Phase 1 clinical trial of NPI-0052 in patients with relapsed or relapsed/refractory multiple myeloma. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), http://clinicaltrials.gov/ct2/show/NCT00461045?term=nct00461045&rank=1. NLM Identifier: NCT00461045 (2000, accessed 16 March 2014).
76. Allegra A, Alonci A, Gerace D, et al. New orally active proteasome inhibitors in multiple myeloma. Leuk Research 2014; 38: 1-9.
77. Ghobrial IM, Kaufman JL, Siegel DS, et al. Clinical profile of single-agent modified-release oprozomib tablets in patients with hematologic malignancies: updated results from a multicenter, open-label, dose escalation phase Ib/2 study. ASH 2013 Annual Meeting Abstract 3184.
78. Tai Y, Chang BY, Kong S, et al. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood 2012; 120: 1877-1887.
79. Edwards CM,. BTK inhibition in myeloma: targeting the seed and the soil. Blood 2012; 120: 1757-8.
80. Imbruvica [package insert]. Sunnyvale, CA: Pharmacyclics, Inc;2014.
81. Pharmacyclics. Study of Bruton's tyrosine kinase inhibitor in subjects with relapsed or relapsed and refractory multiple myeloma. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), http://clinicaltrials.gov/ct2/show/NCT01478581?term=nct01478581&rank=1. NLM Identifier: NCT01478581 (2000, accessed 16 March 2014).
82. Pharmacyclics. Study of the Bruton's tyrosine kinase inhibitor in combination with Carfilzomib (Kyprolis), in subjects with relapsed or relapsed and refractory multiple myeloma. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), http://clinicaltrials.gov/ct2/show/NCT01962792?term=nct01962792&rank=1. NLM Identifier: NCT01962792 (2000, accessed 16 March 2014).
83. 1 antagonist in patients with relapsed/refractory multiple myeloma (MM) or Waldenstrom's macroglobulinemia (WM). ASH Annual Meeting 2013; Abstr 653.
84. University of Chicago. Selinexor, carfilzomib, and dexamethasone in treating patients with relapsed or refractory multiple myeloma (SINE). ClinicalTrials.gov [Internet]. National Library of Medicine (US), https://clinicaltrials.gov/ct2/show/NCT02199665?term=selinexor&rank=4. NLM Identifier: 02199665 (2000, accessed 15 December 2014).
85. Karyopharm Therapeutics and H Lee Moffitt Cancer Center and Research Institute. Selinexor (KPT-330) and pegylated liposomal doxorubicin for relapsed and refractory multiple myeloma. ClinicalTrials.gov [Internet]. National Library of Medicine (US), https://clinicaltrials.gov/ct2/show/NCT02186834?term=selinexor&rank=18. NLM Identifier: NCT02186834 (2000, accessed 15 December 2014).
86. Shah JJ, Zonder JA, Cohen AD, et al. ARRY-520 shows durable response in patients with relapsed/refractory multiple myeloma in a phase 1 dose-escalation study. ASH Annual Meeting 2011; Abstr 1860.
87. Shah JJ, Zonder JA, Cohen A, et al. The novel KSP inhibitor ARRY-520 is active both with and without low-dose dexamethasone in patients with multiple myeloma refractory to bortezomib and lenalidomide: results from a phase 2 study. ASH Annual Meeting 2012. Abstr 449.
88. Chari A, Htut M, Zonder JA, et al. A phase I study of ARRY-520 (filanesib) with bortezomib in relapsed or refractory multiple myeloma. ASH Annual Meeting 2013. Poster 1938.
89. Shah JJ, Feng L, Thomas SK, et al. Phase I study of the novel kinesin spindle protein inhibitor ARRY-520 + carfilzomib (Car) in patients with relapsed and/or refractory multiple myeloma. ASH Annual Meeting 2013. Abstr 1982.
90. Humphries MJ, Anderson D, Williams L, et al. ARRY-520 combined with pomalidomide displays enhanced anti-tumor activity in preclinical models of multiple myeloma. ASH Annual Meeting 2013. Abstr 3167.
91. Lonial S, Shah JJ, Zonder J, et al. Prolonged survival and improved response rates with ARRY-520 in relapsed/refractory multiple myeloma (RRMM) patients with low α-1 acid glycoprotein (AAG) levels: results from a phase 2 study. ASH Annual Meeting 2013. Abstr 285.
92. Touzeau C, Douseet C, LeGouill S, et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia 2014; 28: 210-212.
93. Matulis SM, Sharp C, Nooka AK, et al. Efficacy of ABT-199 in multiple myeloma. ASH Annual Meeting 2013. Abstr 4453.
94. AbbVie. Study evaluating ABT-199 in subjects with relapsed or refractory multiple myeloma. ClinicalTrials.gov [Internet]. National Library of Medicine (US), https://clinicaltrials.gov/ct2/show/NCT01794520?term=abt-199&rank=12. NLM Identifier: NCT01794520 (2000, accessed 15 December 2014).
95. AbbVie. A study evaluating ABT-199 in multiple myeloma subjects who are receiving bortezomib and dexamethasone as standard therapy. ClinicalTrials.gov [Internet]. National Library of Medicine (US), https://clinicaltrials.gov/ct2/show/NCT01794507?term=abt-199&rank=9. NLM Identifier: NCT01794507 (2000, accessed 15 December 2014).
96. Aftab BT, Anderson DJ, LeMoigne R, et al. Pre-clinical activity of the novel, first-in-class p97 inhibitor, CB-5083, in multiple myeloma. ASH Annual Meeting 2014. Abstr 4701.
97. Cleave Biosciences, Inc. A phase I study evaluating CB-5083 in patients with relapsed/refractory multiple myeloma [CLC-102]. ClinicalTrials.gov [Internet]. National Library of Medicine (US), https://clinicaltrials.gov/ct2/show/NCT02223598?term=cb-5083&rank=2. NLM Identifier: NCT02223598 (2000, accessed 15 December 2014).
98. Ying W, Zhenjian D, Sun L, et al. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 2012; 11: 475-484.
99. Emory University. A phase I study of ganetespib +/- bortezomib in patients with relapsed and/or refractory multiple myeloma. ClinicalTrials.gov [Internet]. National Library of Medicine (US), https://clinicaltrials.gov/ct2/show/NCT01485835?term=ganetespib+myeloma&rank=1. NLM Identifier: NCT01485835 (2000, accessed 15 December 2014).
100. Shah S, Dowell J, Greene S,. Evaluation of clinical pharmacy services in a hematology/oncology outpatient setting. Ann Pharmacother 2006; 40: 1527-1533.
101. Valgus JM, Faso A, Gregory KM, et al. Integration of a clinical pharmacist into the hematology-oncology clinics at an academic medical center. Am J Health-Syst Pharm 2011; 68: 613-619.